Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CK-3828136 · AMG-594, CK-136

Other · developed by Cytokinetics

Phase 1 Most advanced trial (none active)
CYTK Developer
1 Registered trials

What is CK-3828136?

CK-3828136 is an investigational drug studied in Healthy Participants.

At a glance

Also known as
AMG-594, CK-136
Drug type
Other
Developer
Cytokinetics (CYTK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
9PN6C05CTD

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05662215 Phase 1 Healthy Participants Terminated CYTK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Participants

More from Cytokinetics

Aficamten FDA approved AMG 423 Phase 1 Omecamtiv Mecarbil Phase 3 Reldesemtiv Phase 3 SB-743921 Phase 1/2 Tirasemtiv Phase 3 Ulacamten Phase 2

Follow CYTK, the company behind CK-3828136

See CYTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CYTK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.